The medicalisation of revolt: A sociological analysis of medical cannabis users

Sociology of Health and Illness

Volumn 35, Issue 1, 2013, Pages 17-32

  Pedersen, Willy ^a   Sandberg, Sveinung ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cannabis culture; Medical cannabis; Medical marijuana; Medicalisation; Symbolic boundaries

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO HEALTH; CANNABIS SMOKING; CHRONIC DISEASE; DOCTOR PATIENT RELATION; FEMALE; HEALTH CARE DELIVERY; HUMAN; HUMAN RELATION; INTERVIEW; LEGAL ASPECT; MALE; MEDICALIZATION; MIDDLE AGED; NORWAY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE;

ADULT; CHRONIC DISEASE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERPERSONAL RELATIONS; INTERVIEWS AS TOPIC; MALE; MARIJUANA SMOKING; MEDICALIZATION; MIDDLE AGED; NORWAY; PHYSICIAN-PATIENT RELATIONS; QUALITY OF LIFE; YOUNG ADULT;

EID: 84872761390     PISSN: 01419889     EISSN: 14679566     Source Type: Journal    
DOI: 10.1111/j.1467-9566.2012.01476.x     Document Type: Article

References (57)

1. Album, D. and Westin, S. (2008) Do diseases have a prestige hierarchy? A survey among physicians and medical students, Social Science & Medicine, 66, 1, 182-8.
2. Amar, M.B. (2006) Cannabinoids in medicine: a review of their therapeutic potential, Journal of Ethnopharmacology, 105, 1-2, 1-25.
3. Appleton, L. (1995) Rethinking medicalisation: alcoholism and anomalies. In Best, J. (ed.) Images of Issues. New York: Aldine.
4. Becker, H. (1953) Becoming a marihuana user, American Journal of Sociology, 59, 3, 235-42.
5. Becker, H. (1974) Conciousness, power and drug effects, Society, 10, 3, 4, 26-31.
6. Berridge, V. (1981) Opium and the People. London: Allen Lane.
7. Bottorff, J., Bissell, L., Balneaves L.G., Oliffe J.L., et al. (2011) Health effects of using cannabis for therapeutic purposes: a gender analysis of user's perspectives, Substance Use & Misuse, 46, 6, 769-80.
8. Broom, D. and Woodward, R. (1996) Medicalisation reconsidered: towards a collaborative approach to care, Sociology of Health & Illness, 18, 3, 357-78.
9. Brown, A. (2007) Novel cannabinoid receptors, British Journal of Pharmacology, 152, 5, 567-75.
10. Chapkis, W. and Webb, R. (2008) Dying to get high. In Chapkis, W. and Webb, R. (eds), Marijuana as Medicine. New York: New York University Press
11. Conrad, P. (2007) The Medicalization of Society. Baltimore: Johns Hopkins University Press.
12. Conrad, P. and Schneider, W. (1992) Deviance and Medicalization. from Badness to Sickness. Philadelphia: Temple University Press.
13. Dahl, H.V. and Frank, V.A. (2011) Medical marijuana - exploring the concept in relation to small scale cannabis growers in Denmark. In Decorte T., Potter, G.R. and Bouchard, M. (eds) World Wide Weed. Farnham: Ashgate.
14. Drug Enforcement Administration (2011) Federal trafficking penalties, available from http://www.justice.gov/dea/agency/penalties.htm (last accessed 13 March 2012).
15. Ernst, G. and Kongsgaard, U.E. (2008) Cannabinoids in pallitative medicine, Tidsskrift for Den norske legeforening, 128, 7, 822.
16. European Monitoring Centre for Drugs and Drug Addiction (2011) Annual Report 2010: Cannabis, available from http://www.emcdda.europa.eu/online/annual-report/2010/cannabis/3 (last accessed 6 December 2011).
17. Gabe, J., Bury, M. and Elston, M. (2009) Key Concepts in Medical Sociology. London: Sage.
18. Gamson, W.A. (1992) The social psychology of collective action. In Morris, A.D. and Mueller, C.M. (eds) Frontiers in Social Movement Theory. New Haven: Yale University Press.
19. Gamson, W.A. (1995) Constructing social protest. In Johnston, H. and Klandermans, B. (eds) Social Movements and Culture. Minneapolis: University of Minnesota Press.
20. Gamson, W.A. and Meyer, D.S. (1996) Framing political opportunity. In McAdam, J.D. and Azald, M.N. (eds) Comparative Perspectives on Social Movements. Cambridge: Cambridge University Press.
21. Grinspoon, L. and Bakalar, J. (1993) Marihuana, the forbidden medicine. New Haven, Yale University Press.
22. GWPharm (2011) Sativex, available from http://www.gwpharm.com/Sativex.aspx (last accessed December 6, 2011).
23. Hall, W. and Degenhardt, L. (2009) Adverse health effects of non-medical cannabis use, The Lancet, 374, 9710, 1383-91.
24. Hinze, S.W. (1999) Gender and the body of medicine or at least some body parts: (re)constructing the prestige hierarchy of medical specialities, Sociological Quarterly, 40, 2, 217-39.
25. Hoffman, D.E. and Weber, J. (2010) Medical marijuana and the law, New England Journal of Medicine, 362, 16, 1453-5.
26. Lamont, M. and Molnár, V. (2002) The study of boundaries in social sciences, Annual Review of Sociology, 28, 167-95.
27. Leung, L. (2011) Cannabis and its derivates: Review of medical use, Journal of American Board of Family Medicine, 24, 4, 452-62.
28. McAdam, D., McCarthy J.D. and Zald, M.N. (1996) Introduction. In McAdam, D. McCarthy, J.D. and Zald, M.N. (eds) Comparative Perspectives on Social Movements. Cambridge: Cambridge University Press.
29. McDonough, M. (2011) Misuse of codeine-containing combination analgesics, Medical Journal of Australia, 194, 9, 486-7.
30. McGabe, S., Knight, J., Teter, C.J. and Wechsler, H. (2005) Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction, 100, 1, 96-106.
31. Mechoulam, R. and Gaoni, Y. (1965) Hashish. Isolation and structure of cannabinolic, cannabidinolic and cannabigerolic acids, Tetrahedron, 21, 5, 1223-4.
32. Modelon, H., Laurenceau, D., Fraugier, E, Miscallef, J., et al. (2007) Abuse and misuse indicators of benzodiazepines and benzodiazepine-like drugs: data from OPPIUM survey in 2005, Fundamental & Clinical Pharmacology, 21, 1, (Suppl. 1.) 51-61.
33. Nettleton, S. (2010) The Sociology of Health and llness. Cambridge: Polity Press.
34. Norwegian Cannabis Forum (2011) Norsk Cannabisforum, available at http://www.norcan.org/ipb/ (last accessed 6 December 2011).
35. Ogborne, A.C., Smart, R. and Adlaf, E.M. (2000) Self-reported medical use of marijuana: a survey of the general population, Journal of Canadian Medical Association, 162, 12, 1685-6.
36. Pacher, P., Batkai, S. and Kunos, G. (2006) The endocannabinoid system as an emerging target of pharmacotherapy, Pharmacological Reviews, 58, 3, 389-462.
37. Page, S., Verhoef, M., Stebbins R.A., Metz, L.M., et al. (2003) Cannabis use as described by people with multiple sclerosis, Canadian Journal of Neurological Science, 30, 3, 201-5.
38. Pedersen, W. (2009) Cannabis use: subcultural opposition or social marginality? A population-based longitudinal study, Acta Sociologica, 52, 2, 135-48.
39. Peretti-Watel, P. (2003) Neutralization theory and the denial of risk: Some evidence from cannabis use among French adolescents, British Journal of Sociology, 54, 1, 21-42.
40. Pertwee, R. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines, British Journal of Pharmacology, 156, 397-411.
41. QSR (2011) Nviv09, available online at http://www.qsrinternational.com/products_nvivo.aspx (last accessed 15 December 2011).
42. Reinarman, C., Nunberg, H., Lanthier, F. and Heddleston, T. (2011) Who are the medical marijuana patients? Journal of Psychoactive Drugs, 43, 2, 128-35.
43. Room, R. (2005) Stigma, social inequality and alcohol and drug use, Drug and Alcohol Review, 24, 2, 143-55.
44. Room, R., Fischer B., Hall, W., Lenton, S., et al. (2010) Cannabis Policy: Moving Beyond Stalemate. Oxford: Oxford University Press.
45. Russo (2011) Taming THC: potential cannabis synergy phytocannabiboid-terpenoid effects, British Journal of Pharmacology, 163, 7, 1344-64.
46. Sandberg, S. (2012) Cannabis culture. A stable subculture in a changing world, Criminology and Criminal Justice, in press.
47. Sandberg, S. and Pedersen W. (2010) Cannabiskultur. Oslo: Universitetsforlaget.
48. Sastre-Garriga, J., Vila, C., Clissold, S. and Montalban, X. (2011) THC and CBD oromucosal spray (Sativex R) in the management of spasticity associated with multiple sclerosis, Expert Review of Neurotherapeutics, 11, 5, 627-37.
49. Stott, C. and Guy, G.W. (2004) Cannabinoids for the pharmaceutical industry, Euphytica, 140, 1-2, 83-93.
50. Taylor, S. (2008) Medicalising cannabis: science, medicine and policy, 1954-2004. Addiction, 15, 5, 462-74.
51. Tilly, C. (2004) Social Movements 1768-2004. Boulder: Paradigm.
52. Tuckett, D., Boulton, M., Olson C. and Williams, A. (1985) Meetings Between Experts. London: Tavistock.
53. Ware, M., Rueda, S., Singer, J. and Kilby, D. (2003) Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use, Journal of Cannabis Therapy, 3, 1, 3-15.
54. Ware, M.A., Adams H. and Guy, G.W. (2005) The medicinal use of cannabis in the UK: results of a nationwide study, International Journal of Clinical Practice, 59, 3, 291-5.
55. West Coast Leaf (2011) West Coast Leaf, available at http://www.westcoastleaf.com/ (last accessed6 December 2012).
56. Zinberg, N.E. (1979) Cannabis and health, Journal of Psychedelic Drugs, 11, 12, 135-44.
57. Zola, I. (1972) Medicine as an institution of social control, Sociological Review, 20, 4, 487-504.